Targeting MET and mTOR Synergistically Overcomes Adaptive Resistance in Glioblastoma
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27177780 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Yunzhan Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Glioblastoma, TOR Serine-Threonine Kinases, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Congressionally Directed Medical Research Programs, NIH HHS.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most aggressive primary brain tumor with limited therapeutic options and extremely poor prognosis. Aberrant activation of the receptor tyrosine kinase MET drives tumor progression, therapeutic resistance, and reduced survival, particularly in the mesenchymal GBM subtype. Given its crucial role in GBM recurrence and progression, we investigated the mechanisms of resistance to MET inhibition using patient-derived glioma-initiating cells (GICs) and orthotopic xenograft mouse models. GICs were treated with the MET inhibitor crizotinib to elucidate the mechanism of adaptive resistance. Prolonged MET inhibition induced a senescent-like phenotype in GICs, associated with downregulation of BNIP3, a mitochondrial protein regulating mitophagy. We showed that BNIP3 downregulation led to activation of mTOR signaling, promoting cellular survival and adaptive resistance. Combining crizotinib with the mTOR inhibitor everolimus effectively suppressed mTOR activity, reduced cell viability, and induced mitochondrial alterations, apoptosis, and necroptosis. In orthotopic GBM xenograft models, combined MET and mTOR inhibition significantly prolonged survival compared with single-agent treatments. Notably, sequential treatment—crizotinib followed by everolimus—further enhanced therapeutic efficacy. These effects were achieved without significant weight loss, supporting tolerability of the treatment regimen. Our findings identify the BNIP3-mTOR axis as a critical mediator of resistance to MET inhibition and demonstrate that combined inhibition of MET and mTOR exhibits significant synergy against GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Translational Medicine, China Pharmaceutical University, Nanjing 210009, China.
- Departments of Radiation Oncology, Penn State University, Hershey, PA 17033, USA.
- Departments of Neurosurgery, Penn State University, Hershey, PA 17033, USA.
- Department of Neurosurgery, Virginia Commonwealth University, Richmond, VA 23298, USA.
- Departments of Pediatrics, Penn State University, Hershey, PA 17033, USA.
- Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
ORCID-Profile: Michael Glantz, Inan Olmez
Förderung
- NINDS NIH HHS
- Congressionally Directed Medical Research Programs
- NIH HHS
- National Institutes of Health
Zitieren
APA
Li, Y., Khan, H., Demirsoy, S., Younis, M., Shi, G., Valensi, H., Bernhardt, W., Lee, J., Machtay, M., Aregawi, D., Glantz, M., Giglio, P., Yang, S., Schell, T., Walter, V., Uzun, Y., & Olmez, I. (2026). Targeting MET and mTOR Synergistically Overcomes Adaptive Resistance in Glioblastoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177780
Vancouver
Li Y, Khan H, Demirsoy S, Younis M, Shi G, Valensi H, et al. Targeting MET and mTOR Synergistically Overcomes Adaptive Resistance in Glioblastoma. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177780
BibTeX
@article{Li2026,
author = {Li, Yunzhan and Khan, Hanif and Demirsoy, Seyma and Younis, Muhammad and Shi, Guilan and Valensi, Hannah and Bernhardt, William and Lee, Jeongwu and Machtay, Mitchell and Aregawi, Dawit and Glantz, Michael and Giglio, Pierre and Yang, Shengyu and Schell, Todd and Walter, Vonn and Uzun, Yasin and Olmez, Inan},
title = {Targeting MET and mTOR Synergistically Overcomes Adaptive Resistance in Glioblastoma},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27177780}
}
EUVIMED